Immunoadsorption with staphylococcal protein A column in autoimmune encephalitis.

Area of Science:

• Neuroimmunology
• Autoimmune Diseases
• Therapeutic Apheresis

Background:

• Autoimmune encephalitis requires prompt treatment, but conventional therapies have limitations and contraindications.
• Limited data exists on Staphylococcal Protein A Column immunoadsorption (SPA-IA) for neuroimmune disorders.
• This study investigates the safety and efficacy of SPA-IA in autoimmune encephalitis.

Observation:

• Retrospective analysis of three autoimmune encephalitis cases unresponsive or contraindicated to first-line treatments.
• Detailed description of clinical features and prognosis before and after SPA-IA therapy.
• Monitoring of antibody titers, fibrinogen levels, and clinical status.

Findings:

• SPA-IA treatment led to significant reductions in antibody titers in most patients.
• Fibrinogen levels remained stable, with no reported bleeding events, indicating a safe profile.
• Patients demonstrated significant improvements in Modified Rankin Scale scores and clinical symptoms post-SPA-IA.

Implications:

• SPA-IA presents a viable and safe therapeutic option for autoimmune encephalitis.
• It offers an alternative for patients with poor response or contraindications to standard treatments.
• Further research into SPA-IA for autoimmune encephalitis is warranted.